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Osteoporosis is the most common skeletal disorder in the United States and is a
major health and socioeconomic problem worldwide (Castelo-Branco, 1998). It is
characterized by a progressive bone weakness due to gradual loss of bone mineral content
and protein matrix leading to increased bone fragility and higher rate of fracture (Castelo-
Branco, 1998). According to the recent National Health and Nutrition Examination
Survey (NHANES), approximately 26 to 38 million adult in the United States have
osteoporosis or are at risk for osteoporosis (Leboff et al., 1999). Osteoporosis is a major
cause of morbidity and mortality which currently cost Americans over $13.8 bill ion
dollars each year in addition to the pain, immobility, depression and inability to perform
tasks (Finkelstein et al., 1998). Costs are expected to exceed $60 billion by the year 2020
if no drastic changes take place (Tolstoi & Levin, 1992).
As the American population gets older, osteoporosis will become an even greater
factor in the health of this society. It is estimated that 50% of women over age 45 and as
many as 90% of women over age 75 have osteoporosis (Melton et al., 1989).
Osteoporosis that is associated with ovarian hormone deficiency following
menopause (postmenopausal osteoporosis) is by far the most common cause of age-
related bone loss. A sharp decrease in ovarian estrogen production is the predominant
r
cause of rapid hormone-related bone los . This rapid phas of bon lo occurs ·thin th
first 10 years following the cessation of menses or surgical r mo at of th ovari ,
resulting in an increased rate of bone turnover and an imbalance b tw en bon ,re orption
and bone formation, thereby accelerating bone loss (Tolstio & Levin, 1992).
Osteoporosis in men is also a significant problem in clinical medicine (Jackson et
aI., 1990). Long-term testosterone deficiency and the resulting reduction in bone mineral
content are important factors that cause osteoporosis in men (Jackson et al., 1990). The
risk for spinal osteoporosis with vertebral fractures increased in men who smoked
cigarettes, drank alcoholic beverages, were obese, and had an associated disease known to
affect calcium or bone metabolism (Seeman et aI., 1983). One out of every eight men
over age 50 will experience a·bone fracture due to osteoporosis (Lipman, 1999).
Prevention of osteoporosis by interrupting the chain of events that leads to bone
fracture is currently the best and most cost-effective approach to osteoporosis (Lindsay,
1993). Appropriate public health strategies during the first, three or four decades of life,
to prevent bone fragility, include having adequate calcium intake, maintaining appropriate
body weight, obtaining adequate physical activity, and avoiding cigarette and alcohol
abuse (United States Department of Health and Human Services, 1988).
Current therapies emphasize the use of anti-resorptive agents, such as estrogen
replacement therapy (ERT) (Lobo, 1995), calcitonin (Gennari et aI., 1994) and
bisphosphonates (Fleisch, 1994). There are also potential bone formation-stimulating
agents such as parathyroid hormone (PTH) (Turner, 1991), 1,25 dihydroxy vitamin D3
(1,25 (OHh vitamin 03) (Raisz, 1993). While these agents may prevent further bone loss
in established osteoporosis, they do not have the capability of restoring bone mass that
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already has been lost (Baron, 1993a). Furth rrnore, the compounds that are report d to
have bone fonning properties are either associated with certain side effects or th y do not
produce bone mass with desirable quality (Turner 1991). It would be most desirable to
discover naturally occurring compounds or synthetic substances that could substitute for
or reduce the use of these types of drugs and at the same time have fewer associated side
effects.
There are some indications that the consumption of a diet rich in fruits,
vegetables, grains, and legumes can reduce the incidence of postmenopausal osteoporosis
(Anderson et aI., 1997). It is reported (Arjrnandi et al., 1996; Anderson et aI., 1997) that
the protective effect of a plant-based diet may be due to the presence of numerous
physiologically-active compounds known as "phytoestrogens" (Arjmandi et aI., 1996).
Phytoestrogens are nonsteroidal plant compounds of diverse structure that may produce
estrogenic responses. Most of the known phytoestrogens are, relatively, weak estrogens,
but they can have potent biological effects when ingested in large quantities (Arjmandi et
aI., 1996). Also, the natural food sources with high concentrations of isoflavones, which
are naturally occurring phytoestrogens, might be equally affective in modulating bone
mass (Gambacciani et aI., 1993). Naturally occurring isoflavones have also been found to
positively affect bone without toxicity, carcinogenicity or other undesirable side effects
(Gambacciani et aI., 1993). The purpose of this study was to detennine whether soy
protein has favorable effects on the indices of bone turnover in both men and women.
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Hypothesis
The hypothesis of this study is that inclusion of soy protein in the diet increases bone
mineral density by suppressing the rate of bone resorption while maintaining or
enhancing the rate of bone fonnation in both men and women.
Objective
The objective of this study was to detennine whether the daily inclusion of 40g soy
protein with nonnal isoflavones (about 90 mg) into the diets of men and women for three
months will positively influence bone metabolism as assessed by favorable alterations in





Osteoporosis is the most common metabolic bone disease. It is characterized by
an imbalance between bone fonnation and bone resorption, resulting in decreased bone
mineral density (BMD) or a reduced amount oftotal bone mass (Eriksen et al., 1994).
The etiology of osteoporosis can be primary (type I and type II) or secondary.
Primary osteoporosis in women begins during the perimenopausal period and is due to
decreased in concentrations of estrogens and androgens (John ton et aI., 1995).
Secondary osteoporosis in men and women is due to various factors such as aging, a
chronic low intake of calcium, use of medications, endocrine disorders, gastrointe tinal
diseases, physical inactivity or immobilization, hyperparathyroidism (Johnston et al.,
1995), cigarette smoking, alcohol abuse, medical diseases that affect calcium or bone
metabolism (Seeman et al., 1983). The disease types differ in tenns of sex and age of
those affected, type and rate of bone loss, and fracture sites (Teitelbaum, 1996).
Vanderschueren et al. (1990) indicated that aging is associated with decreased in rate of
bone foonation rather than increased rate of bone resorption. Results from their study of
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men and women showed that bone and serum osteocalcin c ncentrations which r fL t
elevated osteoblastic activity and increased rate of bone formation wer high In. m n
than in women with average age of (58.3±1.2) years and an age-related d cline was
observed in both sexes.
Osteoporotic fractures usually involve the hip, spine, and wrist (T it lbaum,
1996). According to the National Institutes of Health (1999) an estimated 10 million
individuals in the United States have osteoporosis and an additional 18 million hav low
bone mass that places them at increased risk for this disabling disease. Osteoporosis is the
underlying factor in more than 1.5 million fractures each year. This includes
approximately 300,000 hip fractures, 700,000 vertebral fractures, 250,000 wrist fractures,
and more than 300,000 fractures at other sites.
The incidence of fractures increases with age (Castelo-Branco, 1998). It is higher
in white than in black individuals and in women than in men (Castelo-Branco 1998).
One out of two women and one in eight men will have an osteoporosis-related fracture at
some time in their life (Seeman et al., 1983). Moreover, after the age of 50 years n arly
one-half of all white and oriental women will sustain at least one osteoporotic bone
I
fracture (Castelo-Branco, 1998).
Three factors in the pathogenesis of osteoporosis should be considered: (1)
changes in the organic matrix which is composed mainly of collagen and several
noncoUagenous proteins such as osteocalcin and osteonectin, (2) an inorganic component
such as hydroxyapatite, and (3) peak bone mass which is achieved in the third decade of
life (Leboff et al., 1999). In adults, any factor that maximizes peak bone mass modities
the risk of developing osteoporosis later in life (Finkelstein et al., 1998).
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The bone remodeling cycle begins with osteoclastic bone resorp ion. Ost obI ts
then migrate to this newly formed cavity and r place the d ficiency with a calcifiabl
organic matrix. It appears that with each remodeling cycle th r i an imp roeptible
deficit in bone formation. Therefore, the total bone loss is the function of th number of
cycles in progress at anyone time. Thus, conditions that increase the rate of bone
remodeling processes increase the rate of bone loss (Castelo-Branco 1998). H redity,
race, sex, age and lifestyle have important effects in regulation of the bone remodeling
cycle (Meiner, 1999).
Overview of Osteoporosis in Women
Osteoporosis is a public health threat that affects over 25 million Americans 80%
of whom are women. Loss of ovarian function increases bone resorption and accelerates
bone loss with bone turnover remaining elevated into the late postmenopausal years,
which is a determinant of osteoporosis (Garnero et aI., 1996b). Osteoporotic risk varies
with ethnic origin. For instance, Caucasian women are at greater risk than African and
Mexican Americans (Looker et aL, 1997) and experience with higher fracture rates
(Silverman & Madison, 1998). About 30% of postmenopausal Caucasian women in the
U. S. are affected by osteoporosis with 16% experiencing vertebral fractures (Melton,
1997). We have a paucity of data on bone density and osteoporotic risk factors in Asians
originating from the Indian subcontinent who now live in the U.S. (Cundy et aL, 1995;
Alekel et aL, 1999) or residing elsewhere (Tobias et aL, 1994; Parker et aL, 1992; Chin et
al., 1997). We do know that osteoporotic fractures usually occur 10 to 20 years earlier in
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Indian men and women residing in eastern ar a than in their st m ounterpart
(Nordin, 1966; Gupta et al., 1967). It is aJso noteworthy that Chin and outh ast
Asians who consume soy products habitually have low osteoporotic fractur and high
BMD, whereas Asians from the Indian subcontinent who do not typically consum. soy
products have been at higher risk of osteoporosis (Kamath et aI., 1999). A collective
conclusion from above studies could be drawn that some of these differences in
osteoporotic risk factors among ethnic groups are inexplicable, but in part may be due to
dietary and exercise-related factors specific to each culture.
Overview of Osteoporosis in Men
Osteoporosis in men can be a major health concern. Although less common than
in women, it is estimated that one-seventh of all vertebral fractures and one-fifth of all hip
fractures occur in men (Jackson, 1993). Men have an increased risk of sustaining
fractures of the hip, spine, and foreann with aging. Moreover, a survey conducted in
Sweden has indicated that, although the age-adjusted incidence of fractures of the hip
may be declining in women, the occurance of such fractures in men is on the rise
(Naessen et aI., 1989). Projected figures suggest that 17% of men will suffer a hip
fracture before they reach the age of 90, leading to significant physical and emotional
problems (Avioli, 1991). Osteoporosis develops less commonly in men than in women
because men have larger skeletons, bone loss starts later and progresses more slowly, and
there is no period of rapid hormonal changes and the accompanying rapid bone loss
(Jackson et aI., 1990).
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There are many causes of osteoporosi in men (Jackson t aI. 1990. For
example, 40-45% of men with spinal osteoporosis and ertebral compression fra ture:
have disorders or conditions that can produce bone loss and caus osteoporosis. The
include hypogonadism, hyperthyroidism, neoplastic diseases and gen tic di ord r as
well as steroid therapy, immobilization, and gastric surgery (Scane et a1. 1993).
Currently, the therapy for established osteoporosis in men is inadequate and no single
agent has been convincingly capable of preventing osteoporotic fractures in men.
However, an animal study conducted by Muhlbauer (1997) showed that natural dietary
components such as soy is capable of inhibiting the increased loss of trabecular bone
density in rats. Emphasis must be given to prevention of bone loss in men (Jackson et aI.,
1990).
Food and Drug Admininstration Approved Therapies for Osteoporosis
The approved drugs for the treatment of osteoporosis are estrog n, calcitonin,
bisphosphonates , and raloxifene.
Estrogen. Estrogens (E2) play important hormonal roles among all vertebrates.
Estrogen replacement therapy (ERT) prevents bone loss due to ovarian hormone
deficiency, and controls bone remodeling (Mundy, 1993; Sue, 1993). Studies show an
estimated 25% reduction of hip fractures and 50% reduction of vertebral fractures in
subjects receiving ERT compared to untreated subjects (Sue, 1993). Estrogen maintains
bone mass by slowing bone turnover which subsequently slows bone resorption and bone
formation (Kalu et al., 1991). It may also indirectly inhibit bone loss by its interaction
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with parathyroid honnone (PTH), calcitonin (en and 1,25 (OH)z vitamin D3 and h Ip
maintain their balance in circulation (Tolstoi et al. 1992). Wh n ovarian honnone
deficiency occurs, estrogen maintains bone integrity by possibly int racting with
receptors on osteoclasts and osteoblasts (Tolstoi et al., 1992; Turner 1991- Raisz 1993;
Mundy, 1993). Zotkova et al. (1996) reported that surgically induced estrogen deficiency
increased serum ionized calcium and phosphate levels in blood as well as insulin-like
growth factor-I (IGF-l) concentrations, and PTH in perimenopausal women. These
parameters return to their preoperative values after short-tenn transdennal estrogen
therapy. Although estrogen is usually considered the most effective therapy in treatment
of osteoporosis, unfortunately its use is associated with increase risk of breast and
endometrial cancers (Nagata et al., 1998).
Bisphosphonates. Bisphosphonates are drugs with structural analogues of
pyrophosphate which combine with hydroxyapatite crystals in bone and inhibits
osteoclast or pre-osteoclast activity (Boonecamp et al., 1986). Thus, they easily reach
their target organ, bone, for which they have remarkably high affinity. This modification
gives the compound a longer biologic half-life in the bone to prevent the osteoclasts cells
from resorpting its mineralized matrix.
The original notion about the mechanism of action of bisphosphonates is based on
their high-binding affinity for skeletal calcium and their prevention of bone crystal
dissolution (Boonecamp et al., 1986). These agents impair the resorptive function of both
mature and immature fonns of osteoclasts (Boonecamp et al., 1986). In the cyclical
therapy, bisphosphonate is administered orally at bedtime for two weeks followed by 13
weeks of a daily supplement of calcium and vitamin D3 to ensure that adequate calcium
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and phosphorus are available for mineralization (Tolstoi t al. 1992). In itro
bisphosphonates stimulate collagen synthe is and fatty acid 0 idation (Boon amp t aI.
1986). Variable effects. e. g. increases or decreases depending on th c IluLar mod 1 at
seen in the production of alkaline phosphatase mitochondrial calcium reLe and cell
replication (Boonecarnp et aI.. 1986). Bisphosphonates impair the development of the
immature osteoclast (Boonecarnp et aI.. 1986) and the function of mature osteoclasts.
They depress chemical signaling to adjacent cells and alter the osteoclast life cycle
(Satom et al.. 1990).
Because the remodeling (repair) process of the skeleton is Linked to osteoclastic
function. there are concerns that these long-lived agents may actually be detrimental to
the skeleton. The major concern is that bisphosphonates might halt the metabolism of the
skeleton. stopping the normal repair process (Satom et al.. 1990).
Bisphosphonates include etidronate. aLendronate sodium. residronate, tiludronate.
ibandronate. and zoledronate, most of which are currently under investigation by the Food
and Drug Administration (FDA). The only bisphosphonate currently approv d by th
FDA in the United States (October 1995) for the therapy of established osteoporosis is
alendronate (Ragsdale et aI.. 1998).
Alendronate has been the most intensively studied bisphosphonate so far (Harris
et al., 1993; Liberman et al., 1995). In a well-designed 3-year study conducted at multiple
sites in the United States and abroad. alendronate increased bone mass of the lumbar
spine by approximately 10% and was associated with a reduction in fracture incidence.
Further evidence is seen when comparing the loss of height between the placebo and the
alendronate treatment groups. Women who did not receive the drug lost an average of I
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inch in height over 3 years, whereas those ho received alendronat lost only em averag
of Y4 inch. Another interesting point about a1endronate therapy is that bon. min ra
density showed incremental increases over the 3 years of treatment p riod; This sugg sts
that alendronate may have an additional positive effect on bone beside its anti-resorptive
ability (Harris et al., 1993; Liberman et al., 1995).
Alendronate is remarkably well tolerated and gastrointestinal side effects which
can occur with bisphosphonates at high doses, are not observed. No oth r sid effects
specifically attributable to alendronate have been observed (Harris et al., 1993' Liberman
et al., 1995). Less than 10% of an oral dose of the drug is absorbed from the gut which
half of it is excreted unchanged by the kidney and the remainder is deposited in the bone
(Tolstoi et al., 1992).
Calcitonin. Calcitonin (CT) has been available as an injectable treatment for
established osteoporosis since 1984 (Tolstoi et al., 1992). The inconvenience of injection
and the resulting side effects have limited the widespread use of injectable calcitonin.
The most common side effects of injectable calcitonin are nausea, with or without
vomiting, diarrhea, local reaction at the injection site, and flushing of the face and hands
(Baron et al., 1993b). In 1995, a new nasal spray formulation, sold under the name,
fosamax, by Merck & Co. Inc., was approved by the Food and Drug Administration.
Similar to bisphosphonates, calcitonin inhibits bone resorption by directly affecting the
osteoclast. Calcitonin reduces osteoclast activity in vitro (Tolstoi et al., 1992) and this
reduction appears to be its major role in vivo. Both in vitro and in vivo data suggest that
calcitonin may have an anabolic osteoblastic effect on bone (Tolstoi et al., 1992) which
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could improve bone quality and reduce the incidence of bone fracture (Baron t al.
1993b). Nasal preparations have been licensed for the treatment of ost oporo is in
several countries. This drug which cost $2,200 to $3,000 annually 100 s it efficacy
after 18-24 months due to production of CT antibodies or down regulation of its receptor
(Tolstoi et al., 1992; Baron et al., 1993b).
Raloxifene. Raloxifene is the most recent FDA approved drug for the treatment of
osteoporosis. Its mode of action differs from those of antiresorptive drugs such as
estrogen and bisphosphonates. Raloxifene suppresses bone resorption which allows bone
fonnation to continue (Anthony et aI., 1997). Hence, individuals who have already lost
bone may benefit from this therapy more so than just the antiresorptive drugs (for further
discussion of raloxifene refer to the following SERMs section).
Selective Estrogen Receptor Modulators (SERMS) and Bone
Selective estrogen receptor modulators are a growmg class of nonsteroidal
compounds with estrogen-like actions in bone and lipid metabolism, and antiestrogenic
actions in the breast tissue (Weryha et aI., 1999). Synthetic compounds such as tarnoxifen,
raloxifene, and ipriflavone, pharmacologically and structurally similar to estrogen, are
effective in preventing or reducing bone loss.
The first SERM, tamoxifen, is a nonsteroidal antiestrogen approved by the US
Food and Drug Administration in 1978 for treatment of people with estrogen receptor-
positive breast cancers (Weryha et aI., 1999). However, similar to estrogen it may prevent
bone loss (Wright et aI., 1994). The results of an animal study have shown that
13
tamoxifen acts as an estrogen agonist and prevents bon los~ due to ovarian honnpn
deficiency (Stewart et aI., 1986). Also there is substantial evidence that in
postmenopausal women, tarnoxifen aids in the preservation of bone density and inhibi,ti,on
of bone resorption without changing bone formation (Robinson et al. 19 6).
Furthermore, Kalu et al. (1991) reported that the action of tarnoxifen on bone is
influenced by the level of circulating estrogen. According to this view at low levels of
estradiol, tamoxifen has estrogen agonist action on bone and in the presence of high
plasma estrogen levels it has an anti-estrogenic action on bone. The beneficial effects of
tarnoxifen on bone have been found in other studies but its major drawback is its
endometrial stimulatory effects (Fomander et al., 1989).
Another SERM, raloxifene, is the latest FDA approved drug for osteoporosis. It
mimics estrogen action in some tissues, while preventing the risk of cancer. Raloxifene
exerts positive effect on both bone and cholesterol without affecting the uterine and
breast tissues (Delmas et al., 1997). Raloxifene is a major alternative to hormone therapy
for bone and unlike tamoxifen does not stimulate the endometrium (Delmas et al., 1997;
Heaney & Draper 1997). However, a drawback of raloxifene is that it may increase hot
flushes in some women (Draper et aI., 1996; Walsh et aI., 1998), thus limiting its use to
those who are well beyond the menopausal transition. The proposed mechanism of action
for SERMs on bone is to decrease bone resorption. Although these potential beneficial
effects of SERMs make them very attractive in preventing and treating osteoporosis,
naturally occurring SERMs such as soy isoflavones may be more acceptable to many
postmenopausal women than the synthetic analogues because they can be obtained via
dietary means.
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Ipriflavone (IP) an isoflavone derivative of plant origin (Ha st n 1983) has b n
used. in preventing and treating postmenopausal osteoporosi (Fujita t al. 1986; Agnusdei
et al. 1989; Agnusdei et al., 1992) and in several models of xperim nta! ost poro i
(Yamazaki et aI., 1986a; Yamazaki, 1986b). The effect of ipriflavone on bon r sorption
seems to be directed to inhibition of preosteoclast recruitment and differ ntiation of
osteoclasts (Morita et aI., 1992; Bonucci et al., 1992). It acts as both anti-resorptive and
bone-forming agent without producing the adverse side effects associated with estrog n
(Melis et aI., 1992; Agnusdei et aI., 1992). A recent study by Arjmandi et a1. (2000),
compared the effect of IP to those of E2 on bone in rats with ovarian hormone deficiency.
The investigators of the study concluded that IP as well as E2 is capable of preventing
loss of bone density due to ovariectomy. Ipriflavone is a promising agent and represents
an attractive alternative for the prevention of osteoporosis in postmenopausal women
particularly in those who present contraindications to estrogen replacement therapy.
Soy Protein
Soy beans are excellent source of protein, fiber, and minerals (Messina, 1999) and
are popular in the diets of Asian countries (Omi et aI., 1994). There are fewer cases of
bone fractures due to osteoporosis and lower incidence of breast cancer in Asian women
compared to women in Western countries where a limited amount of soy products are
included in their diets (Zava, 1994; Omi et aI., 1994). Asians consume 20-50 times more
soy-based food per capita than do Americans (Kim et aI., 1998).
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Soybeans are unique among the legumes becau e theyar a cone ntrat d ourc of
isoflavones (Messina, 1999). lsoflavones are a subcla of flavonoids (Me in 1999
containing flavone nucleus which is composed of two b nzene ring link d through a
heterocyclic pyrane ring (Messina, 1999). There are ,about 500 varieties of flavonoids
each possessing many different phannacological and biochemical properties (Brandi
1993). As drug applications, some flavonoids produce anti-microbial, anti-asthmatic or
estrogenic activities (Brandi, 1993). The soy isoflavones have estrogenic effects of
approximately 1x 10-5 the activity of the E2, the natural female sex hormone (Brandi,
1993; Barnes et 811., 1993; zava, 1994).
The pnmary isoflavones present m soybeans are genistein (4,5,7-
trihydroxyisoflavone) and daidzein (4,7-dihydroxyisoflavone) (Messina, 1999).
The similarity in structure between the isoflavones and estrogen and the weak
estrogenic properties of isoflavones provided the initial basis for sp culation that they
may promote bone health. Another speculation about the benefits of isoflavones wa the
similarity in chemical structure between the soybean isoflavones and th.e synthetic
isoflavone, 7-isopropoxy-3-phenyl-4H-l-benzopyran-4-one (ipriflavone) which was
shown to increase bone mass in postmenopausal women (Messina, 1999) and act as both
an anti-resorptive and a bone fonnating agent without producing estrogenic side effects
(Brandi, 1993; Gambacciani et 811.,1993). Ipriflavone also can be used as an alternative
treatment at the level of 600-1200 mg per day for prevention of osteoporosis in
postmenopausal women who exhibit contraindications to ERT (Gambacciani et 811., 1993;
Head, 1999).
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Studies have shown the potential effects of oy protein on both 0 teobla ts and
osteoclasts. The findings of In vitro and in vivo studie by Blair et al. (1996) indicat d
that when overectomized rats were given genistein (44 Ilmol/d) for four w k they had
12% higher (p<O.005) dry femural mass than the control group. The in vitro findings of
their studies showed that genistein suppressed osteoclastic activity with a low potential
for toxicity. In a study by Fanti et aI. (1998), tibial bone mineral loss was reduced
significantly after 21 days after subcutaneous injection of 5 and 25 Ilg genistein/g body
weight to ovariectomized rats. Ishimi et al. (1999) looked at the effects of genistein and
E2 on bone in ovariectomized mice. Both genistein and E2 restored the marked bone loss
occurred in the distal metaphysis of the femoral cancellous bone after ovariectomy.
However, only E2 restored the loss in uterine weight following ovariectomy indicating
that genistein exhibits estrogenic activity in borte but not in uterus (Ishirni et aI., 1999).
A study of soy milk peptides conducted by Omi et a1. (1994) showed that regular
soy milk protein, high-molecular soybean milk peptides and low-molecular soyb an milk
peptides all increased HMO and mechanical bone strenth in comparison with casein d it
(control). The suggested mechnism may be increasing the intestinal calcium absorption,
by some peptides presented in bovine bone. However, additional research is needed to
identify the components of soybeans which influence calcium absorption and bone
metabolism.
Estrogenic Effect of Isoflavones
Phytoestrogens or plant estrogens including isoflavones, coumestans, and lignans
have been identified in whole grains, fruits, and vegetables. Soy isoflavones including
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genistein, daidzein, and glycitein are tructurally similar to E2 are r port d to protect
against chronic diseases such as osteoporosis breast cancer, and cardiovascular di eas
(Kurzer & Xu 1997). Isoflavones exert an estrogenic effect on the central nervous
system, stimulate growth of the genital tract in female mice, and bind to estrogen
receptors (Liberman, 1996). Shutt and Cox (1972) determined that phytoestrogens bind
to estrogen receptors but, in comparison with E2, have much lower binding affinity for
estrogen receptors.
In postmenopausal women consuming 130 mg isoflavones/day, Kurzer (unpublished
observations) found a significant decrease in estrone sulfate (E,S04; p=0.002), increase in
sex hormone binding globulin (SHBG) (p=0.04), and trends toward decreased 17p·
estradiol (E2) and estrone (E I) with increased isoflavone intake. Initially, soy isoflavones
were thought to act purely as hormones. However, the actions of isoflavones are quite
diverse with no single action explaining all their in vivo and in vitro [fects (Setchell &
Adlercreutz, 1988; Setchell, 1995; Adlercreutz, 1995). lsoflavone are thought to inhibit
protein tyrosine kinase, have antioxidant effects (Kurzer & Xu, 1997), and arrest cell
growth by interfering with signal transduction (Higashi & Ogawara, 1994). There is
some evidence that isoflavones in vitro may also inhibit aromatase (Adlercreutz et aI.,
1993), the rate-limiting enzyme in estrogen synthesis. Thus, these data suggest that one




Isoflavones, Bone, and Biochemical Markers of Bone
Recent animal work and one published human study indicate that soy and/or oy
isoflavones increase bone density. The latter study (Potter et aI., 1998) was designed to
examine the lipid-related effects of soy protein and isoflavones, but also indicated that
isoflavone-rich soy increased lumbar spine BMD and BMC in postmenopausal women.
However, there are no published long-term studies in early postmenopausal women
documenting their effect on BMD or BMC. Alekel and colleagues (1999) conducted a
24-week study in perimenopausal women. Their results indicated that percentage change
in lumbar spine BMD or BMC did not decline in the isoflavone-rich soy group; however
significant loss occurred in the control group who were consuming whey protein and loss
approached significance in the isoflavone-deficient group for BMD.
Isoflavones such as genistein and daidzein aside from their bone protective effects
also have additional health benefits including reducing the risk of breast cancer (Ingram
et aI., 1997) and improving lipid profiles, hence reducing the risk of cardiovascular
disease (Ingram et aI., 1997). These phytoestrogens normally compete with estradiol for
binding to estrogen receptors and may, therefore, interfere with estrogen-induced cellular
proliferation (Nagata et ai., 1998). A study on female mice showed that the estrogenic
activity in three isoflavones: daidzein, genistein, and glycitein was 1000-5000 times
lower than that of E2 (Song et aI., 1999). However, with increased levels of dietary intake,
these isoflavones can play an important role in reducing the incidence of estrogen









In a study by Arjmandi et al. (1996) markers of bon formation (alkalin
phosphatase) and resorption (tartrate-resistant acid phosphatase) w re gr at r in
ovariectomized rats consuming soy protein compared to sham-operated control rats.
However, vertebral and femoral bone densities were also significantly higher in the soy
fed compared with ovariectomized control rats with vertebral bone density similar to that
in the estrogen-treated group. In support of these observations calcium and phosphorus
levels of the vertebrae were higher in soy-fed rats compared to sham-operated controls.
Results from this research and another recent study (Harrison et al., 1998) suggest that
bone formation stimulated by soy protein and/or its isoflavones exceeds the resorption
induced by ovariectomy. Other studies have found the effects of cournestrol in vitro that
have been shown to inhibit bone resorption and stimulate mineralization (Tsutsurni et a1.
1995). Yet, the findings of the study by Alekel et al. (1999) in perimenopausal women on
soy isoflavones appear to confirm the animal findings by Arjmandi et al. (1996) in th rat
model. In the study by Alekel et a1. (1999), the analyses of the biochemical marker of
bone indicated that bone formation appeared to be maintained and bon resorption wa
unaltered in the isoflavone-treated group throughout the 24 weeks of treatment. Whereas,
these results did not observed in the isoflavone-deficient soy protein or control group.
Based on these findings from the biochemical markers of bone turnover, soy isoflavones
do not appear to decrease bone resorption as does estrogen therapy but it may prevent a
decrease in bone formation which otherwise typically occurs during the menopausal
transition (song et al., 1999). Thus, the mechanism by which isoflavones appear to
attenuate bone loss may involve osteoblast stimulation and thus maintenance of bone





al. (1996, 1998b) suggest a role for IGF-I in modulating th ffi t. Thi qu tion of
whether isoflavones inhibit bone resorption or stimulate bon fonnation ne d to b
further studied.
Isoflavones, Protein Intake, Mineral Metabolism, and Calcium Absorption
It has also been suggested that a soy protein diet may protect against bone loss by
mechanisms independent of its estrogenic effects. For example, soy foods are a good
source of calcium. Also, isoflavones may enhance intestinal calcium absorption, similar
to the direct estrogen-enhancing effects on calcium uptake in vitro (Arjmandi et aI.,
1993). Further, a high soy protein diet may result in less urinary calcium loss compared
to diets high in animal protein. Breslau et al. (1988) compared urinary losses of calcium
in high soy versus high animal protein diets. Urinary calcium loss with the soy protein
was about 50% of that of the animal protein diet. This may be due to the sulfur-containing
amino acids in animal protein. A related question posed in light of this study is whether the
calcium recommendations (age 50+y, 1200 mg/d) for Caucasians should apply to Asians
who typically consume ~500 mg/d (Pun et al., 1990) and whose body and skeletal sizes are
smaller. A study (Kung et aI., 1998) in non-osteoporotic postmenopausal Chinese women
found that calcium absorption with a 600 mg supplement was 58%, during the unmodified
period was 60%, but rose to 71% during calcium deprivation «300 mg/d). These
absorption values are two-fold higher than what has been reported in Caucasians (Heaney et
aI., 1989) or African Americans (Dawson-Hughes et aI., 1993). The difference in calcium




which provide 41% of their calcium compared. with the U.S. vegetabl and oy int~ hioh
provide <10% of their calcium (Lau, 1995). The issue of plant- v r us animal-bas d di ts
calcium absorption, ethnicity, and bone is not fully understood let alone that of i oflavon s
and calcium balance.
Soy Protein or Its Isoflavones, IGF-I and Its Binding Proteins
The effects of growth hormone on bone are likely mediated locally through IGFs
(Jones & Clemmons, 1995). Bone cells synthesize both IGF-I and IGF-II, while IGF-I is
more potent in stimulating osteoblasts (Zhang et al., 1991), increasing collagen synthesis
and matrix apposition (Hock et al., 1988). Serum IGF-I declines with age in both sexes
(Yamamoto et al., 1991) but also has been shown to decline immediately after menopause
(Romagnoli et al., 1993). Administration of IGF-I stimulates bone turnover (Bianda et
al., 1997), similar to growth hormone (Brixen et al., 1995), and is thought to playa rol in
regulating bone remodeling (Boonen et al., 1996). In addition, IGF-I concentrations are
correlated positively with bone mass in pre- (Romagnoli et al., 1993), peri- (Nasll et al.,
1997), and post-menopausal women (Boonen et al., 1996).
This is complicated by the finding that IGF-I, but not growth hormone (GH)
(Brixen et al., 1995), stimulates production of 1,25(OHh vitamin D in vivo (Bianda et al.,
1997), likely through enhancing renal la-hydroxylase activity. Furthermore, GH may be
the influence of binding proteins on IGF action. The major serum binding protein for
IGF-I, IGFBP-3 (Baxter, 1987) decreases with age but these changes are not necessarily
associated with decreases in estrogen. In perimenopausaJ women, serum IGFBP-2 was
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inversely related and IGFBP-3 was directly related to IOF-I d pi e th lac of dir t
relation of IGFBP-2 to bone density (Nasu et a!., 1997). In contrast rum 10 BP-3
concentrations were reduced in young osteoporotic men (Johansson t al. 1997)
suggesting a role for IGF binding proteins in addition to IGF-I in bon m taboli m.
Circulating IGFBPs not only may influence the effects of IOF-I on bone but other
hormones can alter the concentration of these binding proteins or modulate IGF receptors
(Johansson et aI., 1997). A recent study by Arjmandi et a1. 1998a examined the effects of
feeding soy protein with isoflavones versus reduced isoflavones to ovariectomized rats with
established bone loss. Results indicated that bone IGF-I mRNA levels was increased
~O.OOl) by both diets but more significantly (p<O.05) in the soy with isoflavones group
suggesting an effect of soy on protein synthesis. However, little is known about the effect
of soy isoflavones on serum IGF-I and its binding proteins in humans which may provide
insight into its purported skeletal effects.
Safety Aspects of Soy Isoflavone Intake
The potential of soy isoflavones to cause toxicity must be considered, despite
epidemiologic observations in many Asian women who consume high isoflavone-
containing diets, but have low rates of breast (Wu et aI., 1998) and endometrial (Wynder
et aI., 1991) cancer. A short-term study of dietary soy intake in premenopausal women
with benign and malignant breast conditions, soy intake was shown to stimulate breast
tissue proliferation (McMichael-Phillips et aI., 1998). However, estrogenic effects in
postmenopausal women are less impressive with only slight increases in vaginal cell
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maturation (Baird et aI., 1995; Wilcox et aL 1990). Whereas in anoth r tud 130 mg
consumption of isoflavones daily had no effects on either vaginal cytology r ndom trial
biopsy (Kurzer, 1997). Unlike estrogens, soy isoflavones (Arjmandi et al., 1998a; 1998b)
or genistein alone (Murrill et aI., 1996) in animal studies have shown no tit rotropic
activity. Furthermore, surgically-induced postmenopausal female macaque who
consumed isoflavone-rich soy did not show proliferation in endometrial or mammary
tissue (Foth & Cline, 1998). Doses of 80 and 120 mg daily used in this study are within
the range of what might be consumed from moderate intakes of soy in humans (Wang &
Murphy, 1994).
Significance of the Research
Inclusion of soy protein in diets is believed to delay the onset on bone loss which
occurs during aging. (Kalu et aI., 1988). Age-related increase in serum PTH and enile
bone loss are not inevitable consequences of aging and may be prevented by food
restriction or by maintaining a soy-protein rich diet (Kalu et al., 1988). Soy is a unique
source of the isoflavones which structurally are similar to the synthetic phytoestrogens
(tamoxifen and IP) that have shown positive bone conserving properties (Arjmandi et al.,
1996). However, It is not known what component of soy affects bone metabolism or by
what mechanism it works (Omi et aI., 1994).
The postmenopausal period typically occupies one-third of a woman's life (Barrett-
Connor, 1993), with more than 40 million in the U.S. now in the postmenopausal phase
(Hargrove & Eisenberg, 1995). Menopause is accompanied not only by symptoms, but
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by greater risks of osteoporosis (Lindsay, 1993). A study conducted by Agnusdei &
Bufalino (1997) showed that isoflavone increased bone density and prevent fracture 10
elderly women with established osteoporosis.
In animals, Arjmandi et al. (1998a), showed that by giving isolated soy protein either
with or without isoflavones, to ovariectomized rats after bone loss was already
established, both diets were somewhat effective in reversing femoral but neither fourth
lumbar bone-density loss.
The effect of soy isoflavones on male bone whether animal or human, has received
little attention. This study provides the first insight as to whether soy protein with normal
isoflavone content is effective in improving markers of bone formation and bone
resorption in males.
Although animal studies have provided us with valuable infonnation on potential
mechanisms of action, controlled clinical trials ultimately must be conducted to confinn




RESEARCH DESIGN AND METHODS
Subject Characteristics
Men and women with diverse ethnic backgrounds, who lived in Stillwater,
Oklahoma or adjacent communities were recruited for this study. A total of 135 mobile
individuals (65 men and 70 women), with self reported joint pain or diagnosed
osteoarthritis ranging in age from 27 to 87 years were included in the study. Subjects
were pre-screened via a phone interview which included a short medical history
questionnaire to identify qualified potential participants. Subjects w re excluded if they
had rheumatoid arthritis, joint pain due to injury, cancer or a history of cancer, type I
diabetes mellitus, kidney disease, gastrointestinal or chronic digestive disorder, or





In a double-blind study, eligible men and women w r r cruited and random!
assigned to either a soy or casein regimen. Neither researchers nor subjects knew in
advance if the subjects are taking soy or casein regimen. Each subject was asked to
consume 40 g soy or casein (placebo) supplement on a daily basis for a fur -month
period. One hundred fifty men and women were initially recruited and randomly assigned
to one of the two treatment groups but only 135 subjects showed up for the second visit
where they gave their baseline blood and 24-hr urine specimens. Sixty-four of the
subjects were on the soy regimen and 71 on the casein regimen. It was made clear to the
study participants that they had an equal chance of being placed on either of these
regimens. The supplements were provided to the subjects on a monthly-basis for daily
consumption of two packets containing a powdered drink mix prepared and donated by
Protein Technologies International (St. Louis, MO). Both regimens supplied equal
amounts of protein (40g) and carbohydrate (18g). The rationale for choosing the oy do e
(40g/day) was based on the amount previously used in clinical studies conducted by
Alekel et al. (1999) and Potter et al. (1998). Both studies showed positiv effect of soy
on bone mineral density in women.
Compliance with the study protocol was monitored via the following means: 1)
subjects were provided with a monthly calendar for recording consumption of the
contents of the provided packets on a daily basis; 2) subjects returned any unconsumed
packets to the investigators on their monthly visits, unused supplies were counted and
recorded; and 3) body weight was monitored. Monthly visits were made and if needed
subjects were advised how to best incorporate the supplement into their diets by reducing
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extra protein intake such as meats, eggs and legumes in order to a oid exce s calorie .
total of 90 subjects (44 men and 46 women) completed the study with 45 subjects in acb
of the two treatments.
Subjects met with the investigators for a total of five visits. Visit 1 includ d a
verbal and a written explanation of the project, signing a consent fonn, a detailed medical
history questionnaire to confirm prescreening findings and to insure that subjects do not
have any of the conditions violating the inclusion/exclusion criteria. Subjects were
scheduled to come back to the study site and instructed regarding blood and urine
collection for their next visit. Visit 2 occurred between the hours of 8-10 a.m. for the
collection of overnight fasted blood samples (20 ml) and a 24-hour urine specimen.
Anthropometric measurements included: height, weight, waist to hip ratio, and percent
body fat were also obtained in this visit. Participants were given their food supplies at this
visit. Visits 3 and 4 were monthly visits for the purposes of replenishing the subject's
food supply, monitoring intake of the supplies as well as body weighl. Visit 5, which was
the final visit, occurred three months from the start of the study and included all mea ures
and assessments which were performed on visit 2. Visiting subject started on the
beginning of April and ended at the end of October of 1999.
Subject Confidentiality
Upon entrance into the study, each subject was assigned an identification number.
This number was used for tracking the subject's records throughout the study. The
subjects' data such as medical history were kept in a secured cabinet with restricted
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access. A number was assigned to each subject and thereafter th ampl from ach
study participant carried a number with no personal infonnation availabl to th
laboratory or data entry personnel.
Blood and Urine Collection
Blood Collection. Fasting venous blood was collected at a designated time from each
subject in vacutainer tubes with appropriate anticoagulants or without anticoagulants at
baseline and at the end of the study. Serum and plasma were separated using 1500x g for
20 minutes within 2 hours of collection and immediately aliquoted into small volumes
and stored at -80°C until required for analyses. In this study, serum bone specific alkaline
phosphatase (B-ALP) activity, total alkaline phosphatase (ALP) activity, tartrate resistant
acid phosphatase (TRAP) activity, serum insuline-like growth factor-I (lGF-I), and 17~­
estradiol (E2) were measured. All the measurements are reported in Sl Units.
Urine Collection. Each subject was asked to collect 24-hours of urine in acid-wa hed
polyethylene containers prior to the day of the blood draws. The subjects provided urine
twice during the study (baseline and at the end of the study). Subjects were instructed on
proper urine collection method and the exclusion of the first void of the day. Total
volume of the urine sample was measured to an accuracy of 0.1 ml and recorded. Urine
was aliquoted from each collection and kept at -20°C for analyses. In this study, we
measured pyrilinks-D, phosphorous, calcium, and magnesium. All the measurements are




Height, weight, and waisthip ratio were obtained at baseline. Waist:hip ratio was
also measured at the final visit. Weight was monitored during each monthly follow-up
visit. Ifweight gain was apparent, counseling was made available to make adjustments in
the diet to prevent further gain. The Lee and Nieman (1996) method were used for
assessing anthropometric measurements.
Weight and Height. Body weight was measured on a Health-O-Meter Continental
Scale Corp. scale (Chicago, IL) and subjects dressed in light clothing without shoes or
jewelry. The height was taken on a Acustat Genetech Stadiometer scale (San Francisco,
CA). Subjects were asked to take a deep breath, stand with their feet at a comfortable
distance apart, and their shoulders and head touching the back of the stadiometer.
Heights were measured to the nearest 0.1 inch.
Waist-to-Hip Ratio. Circumferences were measured with measuring tap whil
subjects were wearing light clothing, relaxed, standing erect, and had their arms at their
sides and feet together. Waist circumference was measured midway between the lower
rib and iliac crest whereas hip circumference was measured at the outermost points of the
greater trochanters (WHO, 1995). Wrist to hip ratio was obtained by dividing waist
circumference to hip circumference.
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Percent Body Fat. Percent body fat as measured u Lng Body ompositional z r
(Biodynamics, Modle 310e). The analyzer was based on the bioimpedance method of
testing and was designed to give a level of accuracy. According to the manufacturer t t
results were based upon regression equations which correlat the bior sistanc method to
the hydrostatic weighing method. Test result are accurate to within ±1.5 percentage
points of body fat with a correlation coefficient of 0.97. For a test, the individual s
gender, age, height and weight were entered into the Analyzer
Body Mass Index. Quetelet's Index were used for indicating body mass index (BMI).
Quetelet's Index were obtained by dividing weight in kilograms by height in meters
squared (Lee & Nieman 1996).
Analytical Assays
Biochemical markers of bone turnover were determined two time during th
study period: at baseline and at the end of the study (three months). Two markers of bone
formation in serum: bone-specific alkaline phosphatase and total alkaline phosphatase
activities and two markers of bone resorption: urinary deoxypyridinoline (OPO) and
serum tartrate resistant acid phosphatase (TRAP) activity were measured at baseline and
three months later. Serum insulin-like growth factor (IGF-1), urinary calcium,
phosphorus, magnesium, and creatinine were measured at the same time points. Serum
levels of 17~-estradiol (E2) were assessed at the beginning and at the end of the study to
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evaluate the estrogenicity of soy protein. Serum and urinary mark I' of bon turnov r
were considered primary outcome variables.
Markers of Bone Formation. The most responsive mar er of formation, s rum bon
specific alkaline phosphatase (B-ALP) activity was measured using an ELISA kit
(Alkphase, Metra Biosystems, Mountain View, CA) (Gomez et ai., 1995). This is an
immunoassay in a microtiter strip format utilizing a monoclonal antibody against bone
ALP which is coated on the strip to capture bone-ALP in the sample. Anti-bone-ALP
antibody at 5 mgIL was coated onto the microtiter plates and dried at 37°C overnight. To
each well of the antibody-coated plate, 125 JlL of buffer (100 mmol/L sodium phosphate
and 150 mmol/L sodium chloride, PH 7.0) was added followed by 20 JlL of bone-ALP
calibrator or serum sample. After 3 h of incubation at room temperature, the plate was
washed with a buffer containing 10 mmol/L sodium phosphate, 0.15 mol/L sodium
chloride, and 0.5 giL Tween-20. Then 150 IJ.L of 2 gIL p-nitrophenyl phosphat substrat
in 0.4 mol/L zinc sulfate, and 2 mmol/L magnesium acetate, pH 10.4, was added to ach
well and incubated for 30 min at room temperature. The reaction was stoIJped with ]00
JlL of 1 mol/L NaOH, and the absorbance was read at 405 nrn with a microplate reader.
The results were a measure of the activity of captured bone-ALP expressed in units/L.
Serum alkaline phosphatase (ALP) was measured using a commercially available
kit from Roche Diagnostics (Branchburg, NJ). Serum ALP was determined using 4-
nitrophenylphosphate and 4-nitrophenoxide ion. The rate of increased absorbance at 405
nm is proportional to the enzyme activity. The test was measured by Cobas Fara II
clinical analyzer (Montclair, NJ). We did not deem it necessary to assess other markers
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of formation, e.g., carboxy-tenninal extension p ptide of typ-I pI collag n b cau 0
the high cost of the measurements and the redundancy of the information that is obtained.
The ALP activity was reported in units/L, where one unit of activity is defined as that
amount of enzyme which will produce one J.UIlol of 4-nitrophenoxid ion p r minute
under the conditions of the assay.
Marker of Bone Resorption. The best urinary marker of bone resorption (Hanson et
aI., 1992), deoxypyridinoline (Dpd) was assessed at baseline and at the end of the study.
Deoxypyridinoline has been shown to be one of the most consistent and reliable bone
resorption assays (Hsin-Shan et aI" 1997). DeoxypyridinoLine was measured by an
ELISA kit (Pyrilinks-D, Metra Biosystems, Mountain View, CA) that uses a monoclonal
antibody which has less than 1% cross-reactivity with free pyridinoline and no
significant interaction with cross-linked peptide (Gamero et aI., 1996a).
Serum tartrate resistant acid phosphatase (TRAP) activity was measured u ing a
commercially available kit from Roche Diagnostics (Branchburg, NJ). Th test is based
on the method by Fabiny-Byrd et a1. (1972), hydrolyzing a-naphthylphosphate by acid
phosphatase to produce a dye which absorbs at 405 nm. Tartrate resistance acid
phosphatase values are expressed in unitslL activity, where one unit of activity is defined
as that amount of enzyme which will produce one ~mol of a-naphthol per minute under
conditions of the assay.
Other Nutritionally-Related Parameters. Urinary creatinine was measured usmg a











concentration was detennined colorimetrically using a kin ti· modification of til Jaffi
reaction (Jaffe, 1886). The rate offonnation of the red colored compl
520 run using the Cobas Fara II clinical analyzer (Montclair NJ).
as measured at
Urine samples for calcium and magnesium were prepar d by diluting 100 IJ.L of
urine sample with 6.00 mL of 0.5% nitric acid and 0.5% lanthanum chloride. Calcium
and magnesium concentrations were determined using Perkin Elmer model 5100
(Norwalk, Connecticut) atomic absorption spectrophotometer.
Urinary phosphorus was measured using a commercially available kit from Roche
Diagnostic (Branchburg, NJ). Inorganic phosphorus reacts with ammonium molybdate in
dilute sulfuric acid to form the unreduced phosphomolybdate complex which is measured
at 340 nm (Daly et al., 1972). The test was performed· using the Cobas Fara II clinical
analyzer (Montclair, NJ). All of these indices were determined at baseline, and at the end
of the study.
Serum IGF-I. Serum IGF-I was extracted and measured using a radioimmunoas ay kit
from Nichols Institute Diagnostics (San Juan Capistrano, CA) (Kalu et al., 1994). Fir t,
IGF-l was extracted from serum using the acid-ethanol procedure. For the acid-ethanol
procedure, 100 IJ.L of serum was placed in polypropylene tubes, acidified by adding 900
IJ.L of acid-ethanol solution to each tube. The tubes were parafilmed, vortexed and
centrifuged at 1300-1500 RCF for 30 min at 4°C. Next, the supernatant was diluted with
RIA buffer consisting of 1.4 mL sodium phosphate (monobasic) to give a final serum
dilution of 1:225. The immunoreactive IGF-I was measured using the manufacturer's
protocol. Fifty IJ.L of extracted, standards serum and controls, 350 ilL of phosphate buffer
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and 100 IJ.L of IGF-I antiserum were added to polypropylene tub s. Th tub w re
vortexed and incubated at room temperature for 1 h. Following incubation 100 ~ of
IGF-I 0125-labeled) was added to each tube, vortexed and the tubes incubat d or 1 -18 h
at 4 (c. Unlabeled goat anti-rabbit immunoglobulin in polyethylene glycol (500 IJ.L) and
normal rabbit serum (50 IJ.L) were added to each tube, vortexed, incubated at room
temperature for 20 min and the tubes centrifuged at 1500 g for 30 min at 4 (C. The
supernatant was discarded immediately and the pellet counted for 4 min using the Cobra
II Series gamma counter. The IGF-I concentrations of the test samples were calculated
from a standard curve generated from recombinant IOF-I standards that were treated in a
similar manner as the serum extracts (Kalu et aI., 1994).
Estradiol. Serum levels of E2 were assessed using double antibody assay for estradiol
from Diagnostic Products Corporation (Los Angeles, CA). This procedure is a sequential
radioimmunoassay in which the sample is preincubated with anti-estradiol antiserum.
Radiolabeled 12sl-Estradiol was then added which competes with estradiol in theerum
for antibody sites. After incubation for a fixed time, separation of bound i achieved by
polyethylene glycol (PEO)-accelerated double-antibody method. Finally, the antibody-
bound fraction was precipitated by centrifuging for 15 minutes at 3000 xg and the
supernatant was discarded immediately by decanting. The pellet was counted for 1 min




Data Management and Statistical Analyses
Data Management. The data from subjects were compiled on a weekly basi into th
central database filing system by a trained graduate student for permanent storage. The
laboratory-generated raw data and printouts were recorded/kept in a secured storage ar a.
All of the original data were stored in a locked cabinet with restricted access.
Data Analyses. Descriptive statistics were calculated for all variables and included
means and standard deviations. The data was analyzed using PC SAS version 6.12 (SAS
Inst., Carry, NC). The primary outcome variables were biochemical markers of bone
formation and bone resorption. Independent sample T-tests were used to assess
treatments (soy vs. control) effect and compare baseline and final values within groups.






Subjects participating in this study included 135 healthy men and women with a
mean (SD) age of 57.6 ±l.l years. Subject dropouts included a total of 45 over the entir
course of the study. Dropouts excluded from statistical analyses. Reasons for
discontinuing included taste aversion, gastrointestinal disturbance, inconvenience of
powdered-protein consumption, or starting a new drug therapy that could affect the
outcome of the study.
A. Anthropometric measurements
A.l. All subjects. Consumption of 40 g soy protein or casein daily for a three-month
period did not significantly increase body weight. However, both dietary protein
regimens: soy protein (p<O.OI) and casein (p<O.02) decreased percent body fat. In the
casein group, there was a significant increase in both waist (p<O.04) and waist-to-hip ratio
(p<O.03). In the soy group, there were no significant differences in these two




A.2. Women only. Women receiving soy protein experienced a significant (p<O.02)
decrease in body fat. There were also a tendency for decreasing percent body fat in cas in
(p<0.09). There were no other observed significant alteration in anthropometric
measurements between baseline and final values in the two treatment groups (Table II).
A.3. Men only. Men receiving soy protein regimen had lower fmal body weight,
albeit not significantly (p < 0.09), in comparison with initial body weight. Percent body
fat tended to increase (p <0.08) in subjects who consumed casein in comparison with
their baseline values. Men in casein group also experienced increases in both waist
(p < 0.04) and waist-to-hip ratio (p <0.01) compared with their corresponding baseline
values. There were no other observed significant differences in anthropometric
measurements within treatment groups among men (Table OJ).
B. Serum Parameters: Serum total alkaline phosphate (ALP), bone specific alkaline
phosphatase (E-ALP), tartrate resistant acid phosphatase (TRAP) activitie , estradiol,
and IGF-I concentration
8.1. All subjects. The effects of dietary regimens on serum total ALP, B-ALP,
TRAP activities, estradiol, and IGF-I concentrations for the entire pool of subjects
are presented in Table IV. Casein regimen increased total ALP (p<O.05) activity
compared to baseline activity. Soy consumption reduced (p<O.03) bone-specific
ALP activity in comparison with the corresponding values. However, the soy
regimen also tcnded to decrease (p<O.08) TRAP activity, a marker of bone
resorption. Both soy (p<O.OOOl) and casein (p<O.04) consumption increased
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serum insulin-like growth factor-I (lGF-n con ntrations (Tab) IV) in
comparison with their corresponding baseline valu .
8.2. Women only. Soy consumption suppressed (p<O.005) serum TRAP activity,
in comparison with baseline values, while had no effect on serum total ALP and
B-ALP activities. In comparison with baseline casein regimen significantly
(p<O.03) increased total ALP activity but tended to decrease (p<O.09) B-ALP
activity. Soy and casein regimens had no estrogenic effects as assessed by serum
E2 levels. Soy consumption increased (p<O.OOOI) serum IGF-I concentrations in
comparison with corresponding baseline (Table V).
B.3. Men only. Soy and casein consumptions had no significant effects on serum
ALP, B-ALP, TRAP activities, and E2• Similar to the findings in women, soy
consumption in men also elevated (p<O.OOOl) serum IGF-I concentrations in
comparison with baseline. Casein consumption also elevated (p<O.05) serum IGF-
I concentrations in men in comparison with baseline (Table VI).
C. Urinary Parameters: Deoxypridinoline (Dpd), Phosphorous (P), Magnesium (Mg), and
Calcium (Ca)
c.l. All subjects. The effects of dietary regimens on urinary Dpd, P, Mg, and Ca
per 24-hr of urine for all subjects are presented in Table VII. Casein regimen
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significantly (p<O.04) increased the urinary excretion of P and tended (p<0.06) to
increase the urinary excretion of magnesium in comparison with baseline valu s.
C.2. Women only. Casein regimen significantly increased urinary excr tions of
Dpd (p<0.05), P (p<0.005), Mg (p<0.002) and Ca (p<0.04), while soy protein
regimen had no such increasing effects (Table VIII).
C.3. Men only. There were no significant changes in 24-hr urinary excretions of
Dpd, P, Mg, and Ca in either soy or casein regimens (Table IX).
D. Differences between [mal and baseline values on treatment.
There was no significant differences in serum (total ALP, B-ALP, TRAP) or
urinary parameters CP, Dpd, Mg, Ca) of interests between the two regimens,
except serum IGF-I. Soy regimen significantly increased (p<O.OI) serum IGF-I
concentrations in comparison with casein regimen (Table X).
E. Differences between final and baseline values on gender
There was no significant differences in serum (total ALP, B-ALP, IGF-I, TRAP)
or urinary (P, Dpd, Mg, Ca) parameters of interests between the two regimens in
men and women (Table XI).
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Table I. Comparison between baseline and final anthropometric data for all subjects in soy and casein treatment
Soy Treatment Casein Treatment
Measurements Baseline Final p-value Baseline Final p-value
Age (y) 57.3±1.6 - - 57.8±1.5 - -
(n=45) (n=45)
Bodyweight (lb) 211.7±6.5 206.3 ± 8.7 P<0.2 195.7±6.1 199.1 ± 8.7 P<0.6
(0=45) (0=45) (n=45) (0=45)
Height (in) 67.9±OA - - 67.8±OA - -
(n=45) (0=45)
Bodyfat % 36.0±1.0 35.1±1.2 P<O.OI 35.3±O.9 35.0±1.1 P<0.02
(n=45) (n=45) (0=45) (n=45)
BMI (kg/mL) 32.4±0.9 31.1±1.2 P<O.3 30.2±0.9 30.6±1.2 P<0.6
(n=45) (n=45) (n=45) (n=45)
Waist (in) 40.l±0.8 40.9±1.0 P<O.2 38.8±0.8 39.9±1.0 P<O.04
(0=45) (0=45) (n=45) (n=45)
Hip (in) 45.3±O.8 44.9±1.0 P<0.9 43.5±0.8 43.9±1.0 P<O.9
(n=45) (0=45) (0=45) (0=45)
WaistlHip Ratio 0.89±0.01 0.91±0.01 P<0.06 0.89±0.01 O.91±0.01 P<O.03




Table II. Comparison between baseline and final anthropometric data for female in soy and casein treatment
Soy Treatment Casein Treatment
Measurements Baseline Final p-value Baseline Final p-value
Age (y) 59.2 ± 2.2 - - 58.7 ± 2.2 - -
(n=23) (n=23)
Bodyweight (lb) 189.7 ± 8.9 187.6 ± 12.4 P<0.9 191.7±8.6 195.9 ± 11.9 P<0.7
(n=23) (n=23) (n=23) (n=23)
Height (in) 64.9 ± 0.6 - 65.9 ± 0.6 - -
(n=23) (n=23)
Bodyfat % 38.8 ± 1.4 38.2 ± 1.6 P<0.02 39.7 ± 1.3 39.2 ± 1.5 P<0.09
(n=23) (n=23) (n=23) (n=23)
BMI (kg/m.l) 31.9±1.4 31.5 ± 1.7 P<0.9 31.2 ± 1.3 31.9 ± 1.6 P<0.7
(n=23) (n=23) (n=23) (n=23)
Waist (in) 38.2± 1.1 38.9 ± 1.4 P<O.1 38.3±1.2 39.2 ± 1.4 P<O.4
(n=23) (n=23) (n=23) (n=23)
Hip (in) 44.8 ± 1.1 44.7 ± 1.5 P<0.8 44.2 ± 1.2 44.8 ± 1.4 P<0.7
(n=23) (n=23) (0=23) (n=23)
Waist/Hip Ratio 0.86 ± 0.01 0.87 ± 0.01 P<0.2 0.87 ± 0.01 0.87 ± 0.01 P<0.6
(n=23) (n=23) (n=23) (n=23)
Values represent mean±SD
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Table III. Comparison between baseline and [mal anthropometric data for male in soy and casein treatment
Soy Treatment Casein Treatment
Measurements Baseline Final p-value Baseline Final p-value
Age (y) 55.4 ±2.4 - - 56.9 ± 2.2 - -
(n=22) (n=22)
Bodyweight (lb) 233.7 ± 9.6 224.9 ± 12.2 P<0.09 199.8 ± 8.7 202.4 ± 12.7 P<0.7
(n=22) (n=22) (n=22) (n=22)
Height (in) 71.0 ± 0.7 - - 69.7 ± 0.6 - -
(n=44) (n=22)
Bodyfat % 33.2 ± 1.5 31.9 ± 1.6 P<0.2 30.0 ± 1.4 30.8 ± 1.6 P<0.08
(n=22) (n=22) (n=22) (n=22)
BM! (kglmL ) 32.8 ± 1.5 30.7 ± 1.7 P<O.1 29.2 ± 1.4 29.3 ± 1.8 P<0.7
(n=22) (n=22) (n=22) (n=22)
Waist (in) 41.9 ± 1.2 42.9 ± 1.4 P<0.6 39.2 ± 1.1 40.7 ± 1.5 P<0.04
(n=22) (n=22) (n=22) (n=22)
Hip (in) 45.9 ± 1.2 45.3 ± 1.5 P<0.9 42.8 ± 1.1 42.9 ± 1.5 P<0.6
(n=22) (n=22) (n=22) (n=22)
WaistlHip Ratio 0.92 ±0.01 0.96 ± 0.01 P<0.2 0.92 ± 0.01 0.94 ±0.02 P<O.OI
(n=22) (n=22) (n=22) (n=22)
Va,lues represent mean±SD
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Table IV. Effect of treatments on serum parameters for all subjects
Soy Treatment Casein Treatment
Serum Parameters Baseline Final P- value Baseline Final P- value
Total ALP 1.39±0.40 1.42±0.35 P<0.5 1.25±O.35 1.34±0.41 P<0.05
(j.1katIL) (n=45) (n=45) (n=45) (n=45)
Bone-Specific 0.43±0.15 0.40±0.14 P<0.03 0.40±0.14 0.39 ±0.15 P<OJ
ALP(f..lkat/L) (n=45) (n=45) (n=45) (n=45)
TRAP (U/L) 3.9±2.9 3.1±0.8 P<0.08 3.1±0.6 3.4±0.7 P<0.6
(n=45) (n=45) (n=45) (n=45)
Estradiol (pg/mL) 52.5±12.8 65.8±16.2 P<0.5 77.9±12.6 96.7±14.9 P<O.3
(n=45) (n=45) (n=45) (n=45)
IGF-I (ng/ml) 114.5±54.8 212.9±150.7 P<O.OOOI 136.4±69.4 171.4±77.3 P<0.04
(n=45) (n=45) (n=45) (n=45)
Values represent mean±SD
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Table V. Effect of treatments on serum parameters for female
Soy Treatment Casein Tr,eatment
Serum Parameters Baseline Final P value Baseline Final P value
Total ALP 1.46±O.40 1.51±O.37 P<O.9 1.26±O,41 1.34±O.46 P<O.03
(~atIL) (n=23) (n=23) (n=23) (n=23)
Bone-Specific O.43±O.14 O.41±O.15 P<O.l O.39±O.13 0.36 ffl.lO P<O.09
ALP(~katIL) (n=23) (n=23) (n=23) (n=23)
TRAP (UIL) 4.5±3.6 3.3±O.8 P<0.005 2.9±O.7 3.6±0.7 P<0.7
(n=23) (n=23) (n=23) (n=23)
Estradiol (pg/mL) 52.5±12.8 65.8±16.2 P<O.5 77.9±12.6 96.7±14.9 P<OJ
(n=23) (n=23) (n=23) (n=23)
IGF-I (ng/ml) lO2.3±55.9 204.3±184.7 P<O.OOOI ] 13.6±65.5 139.8±69.1 P<O.3




TABLE VI. Effect of treatments on serum parameters for male
Soy Treatment Casein Treatment
Serum Baseline Final p- value Baseline Final P- value
Parameters
Total ALP 1.3±O.3 1.3±O.3 P<O.4 1.2±O.3 l.3±O.4 P<O.5
(f.lkatIL) (n=22) (n=22) (n=22) (n=22)
Bone-Specific O.42±O.13 O.39±O.13 P<O.l O.41tO.lS O.42±O.19 P<O.9
A LP(J,lkat/L) (n=22) (0=22) (n=22) (n=22)
TRAP 3.lt1.8 2.9±O.8 P<O.7 2.9±0.9 3.S±O.7 P<O.7
CUlL) (n=22) (n=22) (n=22) (n=22)
Estradiol (pglmL) 19.1±13.1 17.9±14.2 P<O.9 31.Stl1.4 17.9±lS.3 p<o.s
(n=22) (n=22) (n=22) (n=22)
IGF-I 134.2±54.2 220.S±117.4 P<O.OOOI 154.3t65.5 209.3±70.6 P<O.05
(nglml) (0=22) (n=22) (n=22) (n=22)
Values represent mean±SD
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Table VII. Effect of treatments on urinary parameters per 24-hr urine for all
Soy Treatment Casein Treatment
Urinary Baseline Final P- value Baseline Final P- value
parameters
Phosphorous 25.9±13.3 28.4±15.1 P<O.7 25.6±11.7 37.8±34.6 P<O.04
(mole/24hr) (n=45) (n=45) (n=45) (n==45)
Pyrilinks-D 78.9±50.9 61.7±49.0 P<O.2 63.7±30.8 77.0±115 P<O.4
(umoV24hr) (n=45) (n==45) (n=45) (n=45)
Magnesium 5.3±3.9 4.7±2.8 P<O.4 4.4±O.2 5.8±5.5 P<O.06
(mole/24hr) (n=45) (n=45) (n=45) (n=45)
Calcium 5.61±5.5 4.5±2.9 P<O.4 3.9±2.4 6.0±5.4 P<O.2
(roole/24 hr) (n=45) (n=45) (n=45) (n=45)
Values represent mean±SD
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Table VIII. Effect of treatments on urinary parameters in 24-hr urine in women
Soy Treatment Casein Treatment
Urinary Baseline Final P- value Baseline Final P- value
parameters
Phosphorous 20.7±10.4 22.0±12.l P<O.8 23.7±13.5 45.4±36.8 P<O.OO5
(mole/24 hr) (n=23) (n=23) (n=23) (n=23)
Pyrilinks-D 69.6±46.7 53.5±32.2 P<O.5 64.1±33.3 97.1±15.6 P<O.05
(umol/24 hr) (n=23) (n=23) (n=23) (n=23)
Magnesium 3.8±1.9 3.7±l.7 P<O.9 3.4±l.3 6.5±7.3 P<O.OO2
(molel24 hr) (n=23) (n=23) (n=23) (n=23)
Calcium 3.9±2.7 4.2±3.5 P<O.8 3.3±l.8 7.3±5.6 P<O.04
(mole/24 hr) (n=23) (n=23) (n=23) (n=23)
Values represent mean±SD
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Table IX. Effect of treatments on urinary parameters in 24-hr urine in men
Soy Treatment Casein Treatment
Urinary Baseline Final P- value Baseline Final P- value
parameters
Phosphorous 31.1±14.2 34.8±15.3 P<O.8 27.8±9.6 29.5±11.6 P<O.9
(molel24 hr) (n=22) (n=22) (n=22) (n=22)
Pyrilinks-D 87.9±54.2 69.0±60.2 P<O.2 63.3±28.7 54.9±26.3 P<O.6
(umoV24 hr) (n=22) (n=22) (n=22) (n=22)
Magnesium 6.7±4.7 5.7±3.3 P<O.3 5.5±2.6 5.1±1.9 P<O.6
(mole/24 hr) (n=22) (n=22) (n=22) (n=22)
Calcium 7.3±6.9 4.8±2.3 P<O.2 4.7±2.7 4.7±2.9 P<O.9






Table X. Differences· by treatment between final and baseline values
Urinary Soy Treatment Casein Treatment p- value
parameters
Phosphorous (mg) 14.8±303.0 -7.8±261.2 P<O.8
(n=45) (n=45)
Pyrilinks-D (ornol) -15.9±37.1 8.4±21.8 P<O.2
(n=45) (n=45)
Magnesium (mg) -5.5±40.5 4.5±25.5 P<O.2
(n=45) (n=45)
Calcium (mg) -8.8±116.3 9.1±71.9 P<OA
(n=45) (n=45)
Serum parameters
Total ALP O.O3±O.2 O.O9±O.3 P<OA
(J..LkatIL) (0=45) (0=45)
Bone-Specific -O.O3±O.O7 -O.Ol±O.O8 P<OA
ALP(J..LkatIL) (0=45) (n=45)
TRAP (UIL) -O.8±4.9 O.2±O.8 P<O.l
(n=45) (n=45)
IGF-I (ng/ml) 98.5±144.9 57.2±21.3 P<O.Ol
(n=45) (0=45)
• Differences calculated by subtracting baseline values from final values
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Table XI. Differences· by gender between final and baseline values
Urinary - Female Male p- value
parameters
Phosphorous (mg) -34.6±229.7 45.9±327.3 P<O.l
(n=46) (n=44)
Pyrilinks-D (nmol) -12.4±25.8 -12.1±35.5 P<O.8
(n=46) (n=44)
Magnesiwn (mg) 5.1±19.3 -6.7±44.4 P<O.2
(n=46) (n==44)
Calcium (mg) 9.1±54.0 -IO.l±128.9 P<O.4
(n=46) (n=44)
Serum parameters
Total ALP O.O7±O.4 O.O4±O.2 P<O.8
(ukat/L) (n=46) (n=44)
Bone-Specific -O.O3±O.O8 -O.OI±O.l P<O.3
ALP(ukat/L) (n=46) (n=44)
TRAP (UIL) -O.8±4.8 O.2±O.7 P<O.l
(n=46) (n=44)
IGF-I (ng/ml) 60.2±130.5 68.7±97.0 P<O.9
(n=46) (n=44)
*Differences calculated by subtracting baseline values from final values





Although the effect of soy protein on bone has been examined in animals
(Arjmandi et a1. 1996; 1998a, 1998b) and two short-tenn human studies, limit d to post-
(Potter, et a1. 1998) or peri-menopausal women (Alekel et aI., 1999), its effect on bone
metabolism in men and women at large has not been studied. Postmenopausal women, in
particular, can benefit from soy consumption since soy products, including its protein
isolate contain considerable amounts of estrogen-like compounds (phytoestrogens)
including isoflavones such as genistein and daidzein (Kanazawa et aI., 1993). Soy
isoflavones are structurally similar to raloxifene and tamoxifen (Agnusdei et aI., 1989)
that positively affect bone and cholesterol metabolisms (Delmas et aI., 1997; Wright et
a!., 1994). Both of these compounds exhibit weak estrogenic (0.2% that of e tradiol)
(Shutt and Braden, 1963) and anti-estrogenic effects (Martin et al., 1978). The estrogenic
action of raloxifen, tamoxifen, and other synthetic SERMs seem to be tissue specific. [n
tissues such as bone and prostate, they act as estrogen agonists, whereas in tissues such as
uterus and breast they act as estrogen antagonists (Love et aI., 1992).
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Our laboratory previously reported that a diet containing oy pro in i olat that i
rich in isoflavones, a class of naturally occurring phytoestrogen , pr vent d 0 ari tom-
induced bone loss in rats (Arjmandi et aI., 1996, 1998a, 1998b). The qu stion 1 ft
unanswered by that study was whether the protective effect of the diet can also be
observed in humans. The present study demonstrates that soy protein isolate with it
nonnal isoflavone content given as a daily supplement has positive effects on some
indices of bone metabolism in both men and women. The findings of a recent clinical
trial by Potter et a1. (1998) have also indicated the importance of soy protein with normal
levels of isoflavones in the diets of postmenopausal women for ameliorating bone mass.
We speculate that the beneficial effects of soy on bone, in part, is due to its isoflavone
content. In support of this view, genistein, one of the isoflavones present in soybeans, has
been shown to effectively prevent ovarian honnone deficiency-associated bone loss
(Anderson et aI., 1997; Fanti et aI., 1998). Two weeks of genistein treatment (1.0 mg/d)
in lactating ovariectomized rats was effective in maintaining trabecular bone tissu in
comparison with ovariectomized control animals (Anderson et al., 1997). Furthermore,
in the same report, genistein stimulated ALP activity in vitro using an osteoblast-like cell
line, suggesting a positive effect on bone formation. Fanti et a1. (1998), also reported that
genistein (5 mg/kg body weight) maintained both cortical and trabecular bones in
ovariectomized rats. However, the aforementioned studies also suggest that the bone-
sparing effect of genistein is biphasic.
Although the soy regimen significantly suppressed the serum index of bone
resorption, TRAP activity, in this study suppressive effect was not as effective as that of
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festrogen (Kalu et al. 1991). Hence, it can be conclud d that th bon prot
soy with normal isoflavone content may not be ideal and only partially pr
Thus, the amount of isoflavones consumed by these subjects may have pr vided a
suboptimal or excessive dose, resulting in only partial protection of bone. How v r
future studies are necessary to explore the bone protective effects of soy prot in or its
isoflavones using more defined study populations, e.g. postmenopausal women not on
hormone replacement therapy, and elderly men and women (older than 70 y).
Furthermore, efficacious doses of isoflavones need to be established on the basis of the
model of osteoporosis, e.g., age or ovarian hormone deficiency-associated bone loss both
in men and women and the type of isoflavone being used.
Although the mechanism by which soy isoflavones exert their protective effects
on bone is unclear, in women, soy's bone protective effects may be additive to that of
estrogen. This view is supported, in part, by the fact that 35 out of 46 women who
participated in this study were on hormone replacement therapy and yet soy r gimen
significantly reduced serum marker of bone resorption (TRAP activity) and tended to
reduce marker of bone resorption (B-ALP activity). These observations imply that soy
isoflavones may exert further estrogenic effects on bone while not having such effect on
other tissues such as uterus. We cannot offer an explanation as to why soy reduced serum
B-ALP activity but not total ALP activity. However, it should be noted that serum total
ALP activity is a nonspecific marker of bone formation which can be influenced by many
other factors.
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In this study, casein was used as a comparative control regim n. Ca in ffi ct
on indices of hone turnover especially IGF-I have not been studied and it is of particular
interest to document its effect on modulating the markers of bone turnover.
Because the soy treatment did not appear to ameliorate the indices of bon
formation in men or women, and yet tended to decreased the indices of bone r sorption
the data suggest that soy protein or its isoflavones may decrease bone resorption resulting
in a net increase in bone formation (formation exceeds resorption).
Both men and women on soy had significantly greater serum IGF-I levels at the
end of the study in comparison with their baseline valuesand casein. It is well recognized
that insulin-like growth factor-I concentrations enhance osteoblastic activity in both
humans (Rosenfeld et al., 1994; Zhang et aI., 1991) and animals (Tanaka et aI., 1994).
Sugimoto et a1. (1997) indicated that insulin-like growth factor-I could be an important
modulator of the rate of bone formation in humans. IGF-I increases coHagen synthesis
and matrix apposition rate (Hock et aI., 1988) both of which are indicativ of enhanced
bone formation rate. These findings confirm earlier observation (Arjmandi et aI., 1998a)
in which soy protein with isoflavones significantly enhanced serum IGF-I lev Is.
Therefore, the elevated serum concentrations of IGF-I may indicate that consumption of
soy protein by humans increases the rate of bone formation and hence, the bone protective
effects of soy, in part, may be due to enhanced rate of bone formation.
The fmdings of this study demonstrated that soy protein Improves body
composition in comparion with casein. In the soy protein group, a decrease in body fat
percentage on average was observed in both men (-1.26%) and women (-0.58%), but the
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decrease only reached a significant level among om n. It ha be n ho in animal
(Barton-Davis et aI., 1999) and. human studies (Welle 1998' art r, 1 5) that IG -I has
a positive effect on lean body mass, specifically by increasing mu cl rna and
decreasing fat mass (Skaggs et aI., 1991). Therefore, the decreases in per nt body fat
observed in the soy group can most likely be attributed to the aforemention d increases in
IGF-I levels among men and women. These observations further suggest that oy protein
or its isoflavones potentially influence bone metabolism, because increased lean body
mass has been reported to correlate with higher bone mineral density (Fox et a1. 2000).
Although calcium absorption was not assessed in this study, soy also may
positively affect bone through enhanced intestinal absorption of calcium. Arjmandi, et al.
have demonstrated that soy protein enhances the in vitro uptake of calcium (unpublished
data) and their results indicated that soy, regardless of its isoflavone content, stimulated
duodenal calcium transport. Their observations are supported by those of Omi et aI.,
(1994), who reported a beneficial effect of a soybean milk-based diet on bone mineral
density of 6-wk-old female rats. The authors suggested that this positive ffect may have
been due to the enhanced intestinal calcium absorption. However, the calcium-
absorption-promoting effects of soy do not appear to be related to vitamin 0 (Barengolts
et aI., 1995). Therefore, the effects of soy protein or its isoflavones on calcium
absorption may not require modulation of serum vitamin D concentrations.
From the findings of this study and our previously published work, it appears that
the mechanism for soy isoflavone action is distinct from that of estrogen. Despite reports
of soy isoflavones, particularly genistein, having mild estrogenic activity, there were
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pronounced differences in blood and urinary markers of bone formation and bon
resoprtion from what is expected of estrogen. For instance, estrogen deer ass rum
IGF-I concentrations (Kalu et al. 1994) whereas, soy increases its levels. strogen
increases urinary excretions of calcium and phosphorus (Arjmandi et ai. 1993) while soy
has no such increasing effects. Estrogen suppresses both indices of bone formation and
bone resorption (Mundy, 1993), whereas in this study soy protein regimen tended to
suppressed the indices of bone resorption. Additionally, the differences between estrogen
and soy protein or its isoflavones become more evident when serum IGF-I is brought into
this equation. In this study, both men and women who consumed soy protein regimen
experienced significant increases in their serum levels ofIGF-I, whereas estrogen
treatment has been reported to reduce serum concentrations ofIGF-I (Span et al., 2000;
Kalu et al., 1994).
Animal studies also support the notion that soy or its isoflavones may be devoid
of any true estrogenic properties. Arjmandi et al. have repeatedly report d (1996, 1998a,
1998b) that in contrast to the uterine-stimulating effect of estradiol, neither soy nor its
isoflavones had demonstrated uterotrophic activity. This suggests that isoflavones have a
different effect on the uterus than does estrogen. In this regard, the isoflavones present in
soy protein may act analogously to tarnoxifen, which is structurally similar to isoflavones,
has an antiestrogenic effect on breast tissue (Kalu et al., 1991 b), and has a proestrogenic
effect on bone (Zava et aI., 1997). However, one study showed an additive effect of
tamoxifen and estrogen on cancellous bone (Zava et aI., 1997) whereas another did not
find any such effect (Messina et aI., 1994). Our findings in this study that soy
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consumption did not modulate serum estrogen levels in both men and women are
supported by the recent observations by Baird et a1. (1995), who showed that 4 wk of so
supplementation did not produce any of the expected estrogenic effects. Furthermore
women with greater urinary isoflavone concentrations did not show a greater estrogenic
responses than did women with modest urinary isoflavone concentrations.
Isoftavones in soy, particularly genistein, have a mild estrogenic effect
approximately lxl0-3 to lxlO-5 that of estradiol (Farmakalidis et aI., 1985). Although the
estrogenic effects of isoflavones may be weak, they may still interfere with the actions of
the more powerful endogenously occurring estrogens in several important ways
(Farnsworth et aI., 1975; Feldman et aI., 1989). When isoflavones are provided along
with estrogen, the effects of estradiol are suppressed (Feldman et aI., 1989). This is in
line with the reported beneficial effect of soy protein of lowering the risk of breast cancer
and colon cancer, because isoflavones are thought to prevent tumor growth by binding to
estrogen receptors on the tumor and hence competitively inhibiting estrogen uptake
(Miksicek, 1993; Shutt, 1967).
In summary, soy protein may have a modest beneficial effect on bone. However,
the bone protective effects of soy or its isoflavones in human require longer-term studies
in which bone density would also be evaluated. In postmenopausal women, research is
needed to determine whether the estrogen dose can be lowered if given in conjunction
with soy-containing products. Moreover, the intake of isoflavones from soy over an
extended period may have a more positive effect on bone than if consumed only during a





The results ofthis study suggest that soy regimen has a favorable effect on bone
metabolism in both women and men by tended to suppress. Elevation of serum insulin-
like growth factor-I concentrations by soy consumption indicate the enhanced osteoblastic
activity and altering bone formation in both women and men.
Longer study duration, measurement of bone density, and more specifically
designed markers of bone resorption such as urinary collagen cross-link-associated N-
telopeptidc of the cross-links of collagen (NTX) are necessary to confirm the findings of
this study.
If the findings of this study are confirmed by other investigators, further studies
will be needed to clarify whether the beneficial effects of soy protein on bone metabolism
is due to soy consumption as such or to its specific constituents such a the isoflavone .
Furthermore, the use of in vivo and in vitro models of osteoporosis are necessary
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